The ongoing trade war between the US and China puts the pharmaceutical sector at risk, with experts warning of potential price spikes for patients. The Trump administration's tariffs and investigations into imported medications raise concerns, as the US imports 75% of its essential medicines. Currently exempt from tariffs, pharmaceuticals may soon be affected. This situation may lead to higher costs for consumers, though a lag in price adjustments exists due to stockpiles and delayed effects in the complex supply chain of medications. The short-term impact might be mitigated as companies absorb costs.
"In the short term, pharmaceutical companies and healthcare providers can eat the spike in costs like they did during the COVID-19 pandemic, thus delaying immediate consumer price impacts."
"Experts warn that without a carve-out for tariff exceptions for pharmaceuticals, prices could skyrocket for US patients amid escalating tariffs and trade tensions with China."
Collection
[
|
...
]